Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst

  • JMP Securities raised the price target to $105 from $90 on Haemonetics Corporation HAE with a Market Outperform rating following the release of Q2 FY23 results.
  • The company posted Q2 EPS of $0.83, better than the $0.67 consensus, and sales of $297.49 million, surpassing the consensus of $269.22 million.
  • The analyst's bullish stance is based on adopting HAE's NexSys PCS platform, and management said it has now transitioned its major domestic customers to NexSys. Vascular Closure (+42% y/y) again exceeded expectations, supporting HAE's two strong growth pillars (Plasma and Hospital) looking out over the next 3-5 years.
  • Mizuho analyst raised the price target from $90 to $100 after Q2 beat on notable out performances in Plasma and Vascular Closure, which drove greater than expected margin gains. 
  • Plasma was driven by a combination of price gains from a sooner-than-expected NexSys/Persona roll-out. 
  • VASCADE MVP outperformed from ongoing new site openings, which helped offset underlying weakness in EP procedures. 
  • Price Action: HAE shares are up 0.41% at $83.91 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!